Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
185
datasets available to search
ShareScore release 0.9.0
Dataset results
185 results for “chronic kidney disease (CKD)”
Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4
ClinicalTrials.gov study NCT04707573. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
ClinicalTrials.gov study NCT05056727. IPD Sharing: YES. Countries: 21. Publications: 0.
Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo
ClinicalTrials.gov study NCT00915876. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis
ClinicalTrials.gov study NCT00112008. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Vitamin D Supplement Study for Stage Three and Four Chronic Kidney Disease (CKD) Patients
ClinicalTrials.gov study NCT01173848. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)
ClinicalTrials.gov study NCT02525263. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years
ClinicalTrials.gov study NCT01073462. IPD Sharing: Not stated. Countries: 1. Publications: 0.
MicroRNA-seq data of aortas from chronic kidney disease (CKD) induced vascualr calcification mouse model
GEO Series GSE159830. Mus musculus. 4 samples. Type: Non-coding RNA profiling by high throughput sequencing.
Experimental mouse model of chronic kidney disease reveals altered cardiac oxidative stress responses in CKD
GEO Series GSE191122. Mus musculus. 8 samples. Type: Expression profiling by high throughput sequencing.
Data from: Prognosis of chronic kidney disease with normal-range proteinuria: The CKD-ROUTE study
Background: Although lower estimated glomerular filtration rate (eGFR) and higher proteinuria are high risks for mortality and kidney outcomes, the prognosis of chronic kidney disease (CKD) in patients with normal-range proteinuria remains unclear. Methods: In this prospective cohort study, 1138 newly visiting stage G2-G5 CKD patients were stratified into normal-range and abnormal-range proteinuria groups. Study endpoints were CKD progression (>50% eGFR loss or initiation of dialysis), cardiovascular events, and all-cause death. Results: In total, 927 patients who were followed for >6 months were included in the analysis. The mean age was 67 years, and 70.2% were male. During a median follow-up of 35 months, CKD progression, cardiovascular events, and mortality were observed in 223, 110, and 55 patients, respectively. Patients with normal-range proteinuria had a significantly lower risk for CKD progression (hazard ratio, 0.20; 95% confidence interval, 0.10-0.38) than those with abnormal-proteinuria by multivariate Cox proportional hazard analysis. We also analyzed patients with normal-range proteinuria (n=351). Nephrosclerosis was the most frequent cause of CKD among all patients with normal-range proteinuria (59.7%). During a median follow-up of 36 months, CKD progression, cardiovascular events, and mortality were observed in 10, 28, and 18 patients, respectively. The Kaplan-Meyer analysis demonstrated that the risks of CKD progression and cardiovascular events were not significantly different among CKD stages, whereas the risk of death was significantly higher in patients with advanced-stage CKD. Multivariate Cox proportional hazard analysis showed that the risk of three endpoints did not significantly differ among CKD stages. Conclusion: Newly visiting CKD patients with normal-range proteinuria, who tend to be overlooked during health checkups did not exhibit a decrease in kidney function even in advanced CKD stages under specialized nephrology care.
PATHOGENESIS OF CHRONIC KIDNEY DISEASE (CKD)
Open the record for dataset details and reuse information.
Is There a Digital Divide in Chronic Kidney Disease (CKD)?
ClinicalTrials.gov study NCT03067779. IPD Sharing: NO. Countries: 1. Publications: 0.
Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients
ClinicalTrials.gov study NCT00958451. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)
ClinicalTrials.gov study NCT01377285. IPD Sharing: NO. Countries: 1. Publications: 0.
Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)
ClinicalTrials.gov study NCT02195323. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Dextromethorphan and Silymarin in Chronic Kidney Disease (CKD) Patients
ClinicalTrials.gov study NCT01091324. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Biomonitoring of Internal Exposure to MNPLs, and Its Effects, in Blood of Patients With Chronic Kidney Disease (CKD)
ClinicalTrials.gov study NCT05155267. IPD Sharing: Not stated. Countries: 1. Publications: 0.
An Observational, Cross Sectional Study to Assess the Prevalence of Chronic Kidney Disease (CKD) in Type 2 Diabetes Patients
ClinicalTrials.gov study NCT02208921. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)
ClinicalTrials.gov study NCT02044653. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
ClinicalTrials.gov study NCT03242967. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.